As of 21 March at 11:56:28 am GMT-4. Market open. Loading Chart for CRBP250321P00010000 ...

As of 11 March at 11:09:31 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

At close: 7 March at 14:05:44 GMT-5 ...

As of March 17 at 11:10:02 a.m. EDT. Market Open.

As of February 20 at 10:31:25 a.m. EST. Market Open.

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened today at $7.10. Effectively assess a stock's ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus ...

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% over the past four weeks, the stock looks well positioned for a trend ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report released on Thursday.